Kratom as an opioid alternative: harm, or harm reduction? A systematic review of literature

References

• Tanguay P. Kratom in Thailand. SSRN 1908849; 2011.
   Google Scholar
• Suwanlert S. A study of kratom eaters in Thailand. Bull Narc. 1975;27:21–27.
   PubMedGoogle Scholar
• Vicknasingam B, Narayanan S, Beng GT, Mansor SM. The informal use of ketum (Mitragyna speciosa) for opioid withdrawal in the northern states of Peninsular Malaysia and implications for drug substitution therapy. Int J Drug Policy. 2010;21:283–88. doi:10.1016/j.drugpo.2009.12.003.
   PubMed Web of Science ®Google Scholar
• Likhitsathian S, Jiraporncharoen W, Aramrattana A, Angkurawaranon C, Srisurapanont M, Thaikla K, Assanangkornchai S, Kanato M, Perngparn U, Jarubenja R. Polydrug use among kratom users: findings from the 2011 Thailand national household survey. J Subst Use. 2018;23:384–89. doi:10.1080/14659891.2018.1436599.
   Web of Science ®Google Scholar
• Charoenratana S, Anukul C, Aramrattana A. Attitudes towards Kratom use, decriminalization and the development of a community-based Kratom control mechanism in Southern Thailand. Int J Drug Policy. 2021;95:103197. doi:10.1016/j.drugpo.2021.103197.
   PubMed Web of Science ®Google Scholar
• Singh D, Narayanan S, Vicknasingam B, Corazza O, Santacroce R, Roman‐urrestarazu A. Changing trends in the use of kratom (Mitragyna speciosa) in Southeast Asia. Hum Psychopharmacol Clin Exp. 2017;32:e2582.
   Web of Science ®Google Scholar
• Boyer EW, Babu KM, Macalino GE, Compton W. Self-treatment of opioid withdrawal with a dietary supplement, Kratom. Am J Addict. 2007;16:352–56.
   PubMed Web of Science ®Google Scholar
• Grundmann O. Patterns of kratom use and health impact in the US—results from an online survey. Drug Alcohol Depend. 2017;176:63–70.
   PubMed Web of Science ®Google Scholar
• Xu KY, Mintz CM, Borodovsky JT, Glaser PEA, Bierut LJ, Grucza RA. Prevalence of Kratom use and co-occurring substance use disorders in the United States. Prim Care Companion CNS Disord. 2021;23:35636.
   Google Scholar
• Covvey JR, Vogel SM, Peckham AM, Evoy KE. Prevalence and characteristics of self-reported kratom use in a representative US general population sample. J Addict Dis. 2020;38:506–13.
   PubMed Web of Science ®Google Scholar
• Smith KE, Dunn KE, Grundmann O, Garcia-Romeu A, Rogers JM, Swogger MT, et al. Social, psychological, and substance use characteristics of US adults who use kratom: initial findings from an online, crowdsourced study. Exp. Clin. Psychopharmacol. 2021a;1:1. doi:10.1037/pha0000518.
   Web of Science ®Google Scholar
• Rogers JM, Smith KE, Strickland JC, Epstein DH. Kratom use in the US: both a regional phenomenon and a white middle-class phenomenon? Evidence from NSDUH 2019 and an online convenience sample. Front Pharmacol. 2021;12:789075.
   PubMed Web of Science ®Google Scholar
• Erowid: Documenting the complex relationship between humans and psychoactives [Internet]; 2022 [accessed 2022 Mar 24]. https://www.erowid.org/
   Google Scholar
• Sage Wisdom. The Salvia divinorum research and information center: the most comprehensive resource for information about this extraordinary psychoactive herb [Internet]; 2022 [accessed 2022 Mar 24]. http://www.sagewisdom.org/
   Google Scholar
• Reddit. Kratom [Internet]; [accessed 2022 Mar 24]. https://www.reddit.com/r/kratom/
   Google Scholar
• Speciosa. Kratom legality map and info [Internet]; [accessed 2022 Mar 24]. https://speciosa.org/
   Google Scholar
• Stanciu C, Ahmed S, Hybki B, Penders T, Galbis-Reig D. Pharmacotherapy for management of “Kratom use disorder”: a systematic literature review with survey of experts. WMJ. 2021;120:54–61.
   PubMedGoogle Scholar
• Kamble SH, Berthold EC, King TI, Raju Kanumuri SR, Popa R, Herting JR, León F, Sharma A, McMahon LR, Avery BA. Pharmacokinetics of eleven kratom alkaloids following an oral dose of either traditional or commercial kratom products in rats. J Nat Prod. 2021;84:1104–12.
   PubMed Web of Science ®Google Scholar
• Sethi R, Hoang N, Ravishankar DA, McCracken M, Manzardo AM. Kratom (Mitragyna speciosa): friend or foe? Prim Care Companion CNS Disord. 2020;22:27410.
   Google Scholar
• Eastlack SC, Cornett EM, Kaye AD. Kratom—pharmacology, clinical implications, and outlook: A comprehensive review. Pain Ther. 2020;9:55–69.
   PubMed Web of Science ®Google Scholar
• Eggleston W, Stoppacher R, Suen K, Marraffa JM, Nelson LS. Kratom use and toxicities in the United States. Pharmacother J Hum Pharmacol Drug Ther. 2019;39:775–77.
   Google Scholar
• Corkery JM, Streete P, Claridge H, Goodair C, Papanti D, Orsolini L, Schifano F, Sikka K, Körber S, Hendricks A. Characteristics of deaths associated with kratom use. J Psychopharmacol. 2019;33:1102–23.
   PubMed Web of Science ®Google Scholar
• Ellis CR, Racz R, Kruhlak NL, Kim MT, Zakharov AV, Southall N, Hawkins EG, Burkhart K, Strauss DG, Stavitskaya L. Evaluating kratom alkaloids using PHASE. PLoS One. 2020;15:e0229646.
   PubMed Web of Science ®Google Scholar
• Yamamoto LT, Horie S, Takayama H, Aimi N, Sakai S, Yano S, Shan J, Pang PKT, Ponglux D, Watanabe K. Opioid receptor agonistic characteristics of mitragynine pseudoindoxyl in comparison with mitragynine derived from Thai medicinal plant Mitragyna speciosa. Gen Pharmacol Vasc Syst. 1999;33:73–81.
   PubMedGoogle Scholar
• Matsumoto K, Horie S, Ishikawa H, Takayama H, Aimi N, Ponglux D, Watanabe K. Antinociceptive effect of 7-hydroxymitragynine in mice: discovery of an orally active opioid analgesic from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2004;74:2143–55.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Hatori Y, Murayama T, Tashima K, Wongseripipatana S, Misawa K, Kitajima M, Takayama H, Horie S. Involvement of μ-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa. Eur J Pharmacol. 2006;549:63–70.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Horie S, Takayama H, Ishikawa H, Aimi N, Ponglux D, Murayama T, Watanabe K. Antinociception, tolerance and withdrawal symptoms induced by 7-hydroxymitragynine, an alkaloid from the Thai medicinal herb Mitragyna speciosa. Life Sci. 2005;78:2–7.
   PubMed Web of Science ®Google Scholar
• Obeng S, Wilkerson JL, León F, Reeves ME, Restrepo LF, Gamez-Jimenez LR, Patel A, Pennington AE, Taylor VA, Ho NP. Pharmacological comparison of mitragynine and 7-hydroxymitragynine: In vitro affinity and efficacy for μ-opioid receptor and opioid-like behavioral effects in rats. J Pharmacol Exp Ther. 2021;376:410–27.
   PubMed Web of Science ®Google Scholar
• Calvache MPG, Obeng S, Leon F, Gamez‐jimenez LR, Patel A, Ho NP, Crowley ML, Pallares V, Mottinelli M, McCurdy CR. In vitro and in vivo pharmacological comparison of Mu‐opioid receptor activity of the Kratom (Mitragyna speciosa) Alkaloid Mitragynine and its Metabolite 7‐hydroxymitragynine. Alzheimer’s Dement. 2021;17:e058605.
   Google Scholar
• Váradi A, Marrone GF, Palmer TC, Narayan A, Szabó MR, Le Rouzic V, Grinnell SG, Subrath JJ, Warner E, Kalra S. Mitragynine/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit β-arrestin-2. J Med Chem. 2016;59:8381–97.
   PubMed Web of Science ®Google Scholar
• Jamil MFA, Subki MFM, Lan TM, Majid MIA, Adenan MI. The effect of mitragynine on cAMP formation and mRNA expression of mu-opioid receptors mediated by chronic morphine treatment in SK–N–SH neuroblastoma cell. J Ethnopharmacol. 2013;148:135–43.
   PubMed Web of Science ®Google Scholar
• Fakurazi S, Rahman SA, Hidayat MT, Ithnin H, Moklas MAM, Arulselvan P. The combination of mitragynine and morphine prevents the development of morphine tolerance in mice. Molecules. 2013;18:666–81.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Yano S, Horie S, Yamamoto LT. Inhibitory effect of mitragynine, an alkaloid with analgesic effect from Thai medicinal plant Mitragyna speciosa, on electrically stimulated contraction of isolated guinea-pig ileum through the opioid receptor. Life Sci. 1997;60:933–42.
   PubMed Web of Science ®Google Scholar
• Khor B-S, Amar Jamil MF, Adenan MI, Chong Shu-Chien A. Mitragynine attenuates withdrawal syndrome in morphine-withdrawn zebrafish. PLoS One. 2011;6:e28340.
   PubMed Web of Science ®Google Scholar
• You CY, Hassan Z, Müller CP, Suhaimi FW. Mitragynine improves cognitive performance in morphine-withdrawn rats. Psychopharmacology (Berl). 2022;239:313–25.
   PubMed Web of Science ®Google Scholar
• Hassan R, Pike See C, Sreenivasan S, Mansor SM, Müller CP, Hassan Z. Mitragynine attenuates morphine withdrawal effects in rats—a comparison with methadone and buprenorphine. Front Psychiatry. 2020;11:411.
   PubMed Web of Science ®Google Scholar
• Wilson LL, Harris HM, Eans SO, Brice-Tutt AC, Cirino TJ, Stacy HM, Simons CA, León F, Sharma A, Boyer EW. Lyophilized kratom tea as a therapeutic option for opioid dependence. Drug Alcohol Depend. 2020;216:108310.
   PubMed Web of Science ®Google Scholar
• Wilson LL, Chakraborty S, Eans SO, Cirino TJ, Stacy HM, Simons CA, Uprety R, Majumdar S, McLaughlin JP. Kratom alkaloids, natural and semi-synthetic, show less physical dependence and ameliorate opioid withdrawal. Cell Mol Neurobiol. 2021;41:1131–43.
   PubMed Web of Science ®Google Scholar
• Cheaha D, Reakkamnuan C, Nukitram J, Chittrakarn S, Phukpattaranont P, Keawpradub N, Kumarnsit E. Effects of alkaloid-rich extract from Mitragyna speciosa (Korth.) Havil. On naloxone-precipitated morphine withdrawal symptoms and local field potential in the nucleus accumbens of mice. J Ethnopharmacol. 2017;208:129–37.
   PubMed Web of Science ®Google Scholar
• Yusoff NHM, Suhaimi FW, Vadivelu RK, Hassan Z, Rümler A, Rotter A, Amato D, Dringenberg HC, Mansor SM, Navaratnam V. Abuse potential and adverse cognitive effects of mitragynine (kratom). Addict Biol. 2016;21:98–110.
   PubMed Web of Science ®Google Scholar
• Harun N, Johari IS, Mansor SM, Shoaib M. Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats. Psychopharmacology (Berl). 2020;237:855–67.
   PubMed Web of Science ®Google Scholar
• Yue K, Kopajtic TA, Katz JL. Abuse liability of mitragynine assessed with a self-administration procedure in rats. Psychopharmacology (Berl). 2018;235:2823–29.
   PubMed Web of Science ®Google Scholar
• Hemby SE, McIntosh S, Leon F, Cutler SJ, McCurdy CR. Abuse liability and therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7‐hydroxymitragynine. Addict Biol. 2019;24:874–85.
   PubMed Web of Science ®Google Scholar
• Meepong R, Sooksawate T. Mitragynine reduced morphine-induced conditioned place preference and withdrawal in rodents. Thai J Pharm Sci. 2019;43(1):21–29.
   Google Scholar
• Japarin RA, Yusoff NH, Hassan Z, Müller CP, Harun N. Cross-Reinstatement of mitragynine and morphine place preference in rats. Behav Brain Res. 2021;399:113021.
   PubMed Web of Science ®Google Scholar
• Sethi R, Miller KA, McAllister R. Kratom: is it the new illicit opiate on the market? Prim Care Companion CNS Disord. 2018;20:27411.
   Google Scholar
• Patel P, Aknouk M, Keating S, Richard I, Kata P, Ali RY, Cheriyath P. Cheating death: a rare case presentation of Kratom toxicity. Cureus. 2021;13(7).
   Web of Science ®Google Scholar
• Zuberi M, Guru PK, Bansal V, Diaz-Gomez J, Grieninger B, Alejos D. Undifferentiated shock and extreme elevation of procalcitonin related to kratom use. Indian J Crit Care Med Peer-Reviewed, off Publ Indian Soc Crit Care Med. 2019;23:239.
   PubMed Web of Science ®Google Scholar
• Mackay L, Abrahams R. Novel case of maternal and neonatal kratom dependence and withdrawal. Can Fam Physician. 2018;64:121–22.
   PubMed Web of Science ®Google Scholar
• Abdullah HMA, Haq I, Lamfers R. Cardiac arrest in a young healthy male patient secondary to kratom ingestion: Is this’ legal high’substance more dangerous than initially thought? BMJ Case Reports CP. 2019;12:e229778.
   PubMedGoogle Scholar
• Eldridge WB, Foster C, Wyble L. Neonatal abstinence syndrome due to maternal kratom use. Pediatrics. 2018;142:e20181839.
   PubMed Web of Science ®Google Scholar
• Matson M, Schenk N. Fatality of 33‐year‐old man involving kratom toxicity. J Forensic Sci. 2019;64:1933–35.
   PubMed Web of Science ®Google Scholar
• Afzal H, Esang M, Rahman S. A case of kratom-induced seizures. Cureus. 2020;12:e6588.
   Web of Science ®Google Scholar
• Boyer EW, Babu KM, Adkins JE, McCurdy CR, Halpern JH. Self‐treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction. 2008;103:1048–50.
   PubMed Web of Science ®Google Scholar
• Sablaban IM, Gautam M. The diagnosis of severe obsessions in the setting of kratom withdrawal and treatment with lorazepam: case report. J Addict Dis. 2020;39:138–39.
   PubMed Web of Science ®Google Scholar
• Stanciu CN, Gnanasegaram SA, Ahmed S, Penders T. Kratom withdrawal: A systematic review with case series. J Psychoactive Drugs. 2019;51:12–18.
   PubMed Web of Science ®Google Scholar
• Khazaeli A, Jerry JM, Vazirian M. Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018;12:493–95.
   PubMed Web of Science ®Google Scholar
• Cheng J, Kmiec JA, Lin L, Glance JB. Treatment of kratom dependence: a case report [Internet]. 50th American Society of Addiction Medicine Annual Conference; 2019 [accessed 2022 Mar 24]. http://www.eventscribe.com/2019/posters/ASAM/SplitViewer.asp?PID=MzM0OTQ4NTYyNTY
   Google Scholar
• Broyan VR, Brar JK, Allgaier Tristen S, Allgaier JT. Long-term buprenorphine treatment for kratom use disorder: a case series. Subst Abus. 2022;43:763–66.
   PubMed Web of Science ®Google Scholar
• Smid MC, Charles JE, Gordon AJ, Wright TE. Use of kratom, an opioid-like traditional herb, in pregnancy. Obstet Gynecol. 2018;132:926–28.
   PubMed Web of Science ®Google Scholar
• Buresh M. Treatment of kratom dependence with buprenorphine-naloxone maintenance. J Addict Med. 2018;12:481–83.
   PubMed Web of Science ®Google Scholar
• Bath M. Buprenorphine-Naloxone treatment of kratom addiction: a unique case report and literature review. Am Acad Addict Psychiatry Annu Meet Sci Symp. 2018.
   Google Scholar
• Hartwell K, Maxwell A. Kratom (Mitragynine) use on the rise: a case series from a VA substance treatment and recovery program. Am J Addict. 2018;27:296–97.
   Web of Science ®Google Scholar
• Bowe A, Kerr PL. A complex case of kratom dependence, depression, and chronic pain in opioid use disorder: Effects of buprenorphine in clinical management. J Psychoactive Drugs. 2020;52:447–52.
   PubMed Web of Science ®Google Scholar
• Weiss ST, Douglas HE. Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: A case series and systematic literature review. J Addict Med. 2021;15:167–72.
   PubMed Web of Science ®Google Scholar
• Sheleg SV, Collins GB. A coincidence of addiction to “Kratom” and severe primary hypothyroidism. J Addict Med. 2011;5:300–01.
   PubMed Web of Science ®Google Scholar
• Hall A, Hall D. Kratom ingestion and emergency care: Summary and a case report. J Emerg Nurs. 2021;47:551–56.
   PubMed Web of Science ®Google Scholar
• Karinen R, Fosen JT, Rogde S, Vindenes V. An accidental poisoning with mitragynine. Forensic Sci Int. 2014;245:e29–e32.
   PubMed Web of Science ®Google Scholar
• Regan GA, Papadakos PJ. Intracerebral hemorrhage after kratom ingestion. J Am Acad Pas. 2021;34:33–36.
   Web of Science ®Google Scholar
• Smith KE, Lawson T. Prevalence and motivations for kratom use in a sample of substance users enrolled in a residential treatment program. Drug Alcohol Depend. 2017;180:340–48.
   PubMed Web of Science ®Google Scholar
• Grundmann O, Veltri CA, Morcos D, Knightes ID, Smith KE, Rogers JM. How essential is kratom availability and use during COVID-19? Use pattern analysis based on survey and social media data. Subst Abus. 2022;43:865–77.
   PubMed Web of Science ®Google Scholar
• Coe MA, Pillitteri JL, Sembower MA, Gerlach KK, Henningfield JE. Kratom as a substitute for opioids: Results from an online survey. Drug Alcohol Depend. 2019;202:24–32.
   PubMed Web of Science ®Google Scholar
• Smith KE, Rogers JM, Dunn KE, Grundmann O, McCurdy CR, Schriefer D, Epstein DH. Searching for a signal: self-reported kratom dose-effect relationships among a sample of us adults with regular kratom use histories. Front Pharmacol. 2022 Mar 1;13:765917.
   PubMed Web of Science ®Google Scholar
• Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (Mitragyna speciosa): User demographics, use patterns, and implications for the opioid epidemic. Drug Alcohol Depend. 2020;208:107849.
   PubMed Web of Science ®Google Scholar
• Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, Prozialeck WC, Boyer E, Balasingam V. Self-Report data on regular consumption of illicit drugs and HIV risk behaviors after kratom (Mitragyna Speciosa Korth.) initiation among illicit drug users in Malaysia. J Psychoactive Drugs. 2020;52:138–44.
   PubMed Web of Science ®Google Scholar
• Saref A, Suraya S, Singh D, Grundmann O, Narayanan S, Swogger MT, Prozialeck WC, Boyer E, Chear NJY, Balasingam V. Self-Reported prevalence and severity of opioid and kratom (Mitragyna speciosa korth.) side effects. J Ethnopharmacol. 2019;238:111876.
   PubMed Web of Science ®Google Scholar
• Singh D, Chear NJY, Narayanan S, Leon F, Sharma A, McCurdy CR, Avery BA, Balasingam V. Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users. J Ethnopharmacol. 2020;249:112462.
   PubMed Web of Science ®Google Scholar
• Behnood-Rod A, Chellian R, Wilson R, Hiranita T, Sharma A, Leon F, McCurdy CR, McMahon LR, Bruijnzeel AW. Evaluation of the rewarding effects of mitragynine and 7‐hydroxymitragynine in an intracranial self-stimulation procedure in male and female rats. Drug Alcohol Depend. 2020;215:108235.
   PubMed Web of Science ®Google Scholar
• Atici S, Cinel I, Cinel L, Doruk N, Eskandari G, Oral U. Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model. J Biosci. 2005;30:245–52.
   PubMed Web of Science ®Google Scholar
• Ilmie MU, Jaafar H, Mansor SM, Abdullah JM. Subchronic toxicity study of standardized methanolic extract of Mitragyna speciosa Korth in Sprague-Dawley Rats. Front Neurosci. 2015;9:189.
   PubMed Web of Science ®Google Scholar
• Sabetghadam A, Ramanathan S, Sasidharan S, Mansor SM. Subchronic exposure to mitragynine, the principal alkaloid of Mitragyna speciosa, in rats. J Ethnopharmacol. 2013;146:815–23.
   PubMed Web of Science ®Google Scholar
• Singh D, Müller CP, Murugaiyah V, Hamid SBS, Vicknasingam BK, Avery B, Chear NJY, Mansor SM. Evaluating the hematological and clinical-chemistry parameters of kratom (Mitragyna speciosa) users in Malaysia. J Ethnopharmacol. 2018;214:197–206.
   PubMed Web of Science ®Google Scholar
• Dorman C, Wong M, Khan A. Cholestatic hepatitis from prolonged kratom use: A case report. Hepatology. 2015;61:1086–87.
   PubMed Web of Science ®Google Scholar
• Takayama H. Chemistry and pharmacology of analgesic indole alkaloids from the rubiaceous plant, Mitragyna speciosa. Chem Pharm Bull (Tokyo). 2004;52:916–28.
   PubMed Web of Science ®Google Scholar
• Brown PN, Lund JA, Murch SJ. A botanical, phytochemical and ethnomedicinal review of the genus Mitragyna korth: implications for products sold as kratom. J Ethnopharmacol. 2017;202:302–25.
   PubMed Web of Science ®Google Scholar
• Berthold EC, Kamble SH, Raju KS, Kuntz MA, Senetra AS, Mottinelli M, León F, Restrepo LF, Patel A, Ho NP. The lack of contribution of 7-Hydroxymitragynine to the Antinociceptive effects of Mitragynine in Mice: a Pharmacokinetic and Pharmacodynamic study. Drug Metab Dispos. 2022;50:158–67.
   PubMed Web of Science ®Google Scholar
• Kamble SH, León F, King TI, Berthold EC, Lopera-Londoño C, Siva Rama Raju K, Hampson AJ, Sharma A, Avery BA, McMahon LR. Metabolism of a kratom alkaloid metabolite in human plasma increases its opioid potency and efficacy. ACS Pharmacol Transl Sci. 2020;3:1063–68.
   PubMedGoogle Scholar
• Chear N-Y, León F, Sharma A, Kanumuri SRR, Zwolinski G, Abboud KA, Singh D, Restrepo LF, Patel A, Hiranita T. Exploring the chemistry of alkaloids from Malaysian Mitragyna speciosa (kratom) and the role of oxindoles on human opioid receptors. J Nat Prod. 2021;84:1034–43.
   PubMed Web of Science ®Google Scholar
• Smith LC, Lin L, Hwang CS, Zhou B, Kubitz DM, Wang H, Janda KD. Lateral flow assessment and unanticipated toxicity of kratom. Chem Res Toxicol. 2018;32:113–21.
   PubMed Web of Science ®Google Scholar
• Warner ML, Kaufman NC, Grundmann O. The pharmacology and toxicology of kratom: From traditional herb to drug of abuse. Int J Legal Med. 2016;130:127–38.
   PubMed Web of Science ®Google Scholar
• Lydecker AG, Sharma A, McCurdy CR, Avery BA, Babu KM, Boyer EW. Suspected adulteration of commercial kratom products with 7-hydroxymitragynine. J Med Toxicol. 2016;12:341–49.
   PubMed Web of Science ®Google Scholar
• Rybarczyk KS. Quantitative analysis of mitragynine in consumer products labeled as kratom. Ann Arbor, Michigan, USA: University of Illinois at Chicago; 2019.
   Google Scholar
• Davidson C, Cao D, King T, Weiss ST, Wongvisavakorn S, Ratprasert N, Trakulsrichai S, Srisuma S. A comparative analysis of kratom exposure cases in Thailand and the United States from 2010-2017. Am J Drug Alcohol Abuse. 2021;47:74–83.
   PubMed Web of Science ®Google Scholar